FDA approves Atezolizumab for Triple-Negative Breast Cancer

The US FDA has granted accelerated approval of a new treatment for triple-negative breast cancer, which is difficult to treat. Further trials are required, but early studies strongly suggest that patients with triple-negative breast cancer benefit from this combination treatment. For further details, click on the link below: https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval?fbclid=IwAR00ZVHpsrp2qMMLx1Z9stNVarNL9Hqs_9WcpWrSO4vgYWFYqZKSKtpYepc